FOLFOX plus PANITUMUMAB (Pmab) according to a “stop-and-go” strategy in first-line in patients (pts) with non-mutated RAS/BRAF metastatic colorectal cancer (mCRC). Results of the FFCD 1605 – OPTIPRIME phase II trial.